NCT07162181View on ClinicalTrials.gov

Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

PHASE2RecruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

August 7, 2025

Primary Completion Date

May 31, 2030

Study Completion Date

May 31, 2030

Conditions
Lymphoma, Non-HodgkinLeukemia, Lymphocytic, Chronic, B-CellB-cell Lymphoma
Interventions
DRUG

Pirtobrutinib

Administered orally.

Trial Locations (6)

100142

NOT_YET_RECRUITING

Beijing Cancer hospital, Beijing

150081

NOT_YET_RECRUITING

Harbin Medical University Cancer Hospital, Harbin

200123

ACTIVE_NOT_RECRUITING

Shanghai East Hospital, Shanghai

300020

NOT_YET_RECRUITING

Blood Institute of the Chinese Academy of Medical science, Tianjin

430022

RECRUITING

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

510060

NOT_YET_RECRUITING

Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT07162181 - Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers | Biotech Hunter | Biotech Hunter